Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

References

• Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen. n. sp. ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159–218. doi: 10.1590/S0074-02761909000200008
   Google Scholar
• WHO. Chagas disease (also known as American trypanosomiasis) [Internet]. 2023 [cited 2022 Sep 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
   Google Scholar
• Durães-Oliveira J, Palma-Marques J, Moreno C, et al. Chagas disease: a silent threat for dogs and humans. Int J Mol Sci. 2024;25(7):3840. doi: 10.3390/ijms25073840
   PubMed Web of Science ®Google Scholar
• Gascon J, Bern C, Pinazo M-J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115(1–2):22–27. doi: 10.1016/j.actatropica.2009.07.019
   PubMed Web of Science ®Google Scholar
• Guhl F, Ramírez JD. Poverty, migration, and Chagas disease. Curr Trop Med Rep [Internet]. 2021 [cited 2021 Feb 11];8(1):52–58. Available from: https://doi.org/10.1007/s40475-020-00225-y
   Google Scholar
• Lidani KCF, Andrade FA, Bavia L, et al. Chagas disease: from discovery to a worldwide health problem. Front Public Health. 2019;7:166. doi: 10.3389/fpubh.2019.00166
   PubMed Web of Science ®Google Scholar
• Brener Z. Biology of Trypanosoma Cruzi. Annu Rev Microbiol. 1973;27(1):347–382. doi: 10.1146/annurev.mi.27.100173.002023
   PubMed Web of Science ®Google Scholar
• Carlier Y, Torrico F. Congenital infection with Trypanosoma cruzi: from mechanisms of transmission to strategies for diagnosis and control. Rev Soc Bras Med Trop. 2003;36(6):767–771. doi: 10.1590/S0037-86822003000600024
   PubMedGoogle Scholar
• Cevallos AM, Hernández R. Chagas’ disease: pregnancy and congenital transmission. Biomed Res Int. 2014;2014:1–10. doi: 10.1155/2014/401864
   Web of Science ®Google Scholar
• Dias JCP, Amato Neto V. Prevenção referente às modalidades alternativas de transmissão do trypanosoma cruzi no Brasil. Rev Soc Bras Med Trop. 2011;44 Suppl 2(suppl 2):68–72. doi: 10.1590/S0037-86822011000800011
   PubMedGoogle Scholar
• Howard JE, Rios C, Ebensperger I, et al. [Congenital Chagas’ disease]. Bol Chil Parasitol. 1957;12(3):42–45.
   PubMedGoogle Scholar
• Wanderley DM, Aranha Camargo LM, de Carvalho ME. Chagas’ disease: registry of an acute transfusional case. Rev Inst Med Trop S Paulo. 1988;30(6):437–440. doi: 10.1590/S0036-46651988000600009
   PubMed Web of Science ®Google Scholar
• Beatty NL, Arango-Ferreira C, Gual-Gonzalez L, et al. Oral Chagas disease in Colombia—confirmed and suspected routes of transmission. Trop Med Infect Dis. 2024;9(1):14. doi: 10.3390/tropicalmed9010014
   PubMedGoogle Scholar
• Dias JCP. Notas sobre o Trypanosoma cruzi e suas características bio-ecológicas, como agente de enfermidades transmitidas por alimentos. Rev Soc Bras Med Trop. 2006;39(4):370–375. doi: 10.1590/S0037-86822006000400010
   PubMedGoogle Scholar
• Filigheddu MT, Górgolas M, Ramos JM. Enfermedad de Chagas de transmisión oral. Med Clínica. 2017;148(3):125–131. doi: 10.1016/j.medcli.2016.10.038
   PubMed Web of Science ®Google Scholar
• Pereira KS, Schmidt FL, Guaraldo AMA, et al. Chagas’ disease as a foodborne illness. J Food Prot. 2009;72(2):441–446. doi: 10.4315/0362-028X-72.2.441
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82–94. doi: 10.1016/S0140-6736(17)31612-4
   PubMed Web of Science ®Google Scholar
• Rassi A, Rassi A, Marcondes de Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am. 2012;26(2):275–291. doi: 10.1016/j.idc.2012.03.002
   PubMed Web of Science ®Google Scholar
• Chapadeiro E. Clinical evolution and morbi-mortality in Chagas disease. Mem Inst Oswaldo Cruz. 1999;94 Suppl 1(suppl 1):309–310. doi: 10.1590/S0074-02761999000700058
   PubMedGoogle Scholar
• De Sousa AS, Vermeij D, Ramos AN, et al. Chagas disease. Lancet. 2024;403(10422):203–218. doi: 10.1016/S0140-6736(23)01787-7
   PubMed Web of Science ®Google Scholar
• PAHO/WHO. World Chagas disease Day 2023 - PAHO/WHO | Pan American Health Organization [Internet]. 2023 [cited 2024 Jan 22]. Available from: https://www.paho.org/en/campaigns/world-chagas-disease-day-2023
   Google Scholar
• Díaz-Bello Z, De Noya BA, Muñoz-Calderón A, et al. Ten-year follow-up of the largest oral Chagas disease outbreak. Laboratory biomarkers of infection as indicators of therapeutic failure. Acta Trop. 2021;222:106034. doi: 10.1016/j.actatropica.2021.106034
   PubMed Web of Science ®Google Scholar
• Molina I, Salvador F, Sánchez-Montalvá A. Posaconazole versus benznidazole for chronic chagas. Disease N Engl J Med. 2014;371:965–966.
   PubMedGoogle Scholar
• Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–1306. doi: 10.1056/NEJMoa1507574
   PubMed Web of Science ®Google Scholar
• Ribeiro V, Dias N, Paiva T, et al. Current trends in the pharmacological management of Chagas disease. Int J Parasitol Drugs Drug Resist. 2020;12:7–17. doi: 10.1016/j.ijpddr.2019.11.004
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419–430. doi: 10.1016/S1473-3099(17)30538-8
   PubMed Web of Science ®Google Scholar
• Crespillo-Andújar C, Comeche B, Hamer DH, et al. Use of benznidazole to treat chronic Chagas disease: an updated systematic review with a meta-analysis. Rostami A, editor. PLOS Negl Trop Dis. 2022;16(5):e0010386. doi: 10.1371/journal.pntd.0010386
   PubMed Web of Science ®Google Scholar
• Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi Carriers. J Am Coll Cardiol. 2017;69(8):939–947. doi: 10.1016/j.jacc.2016.12.023
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascón J, Barreira F, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021;21(8):1129–1140. doi: 10.1016/S1473-3099(20)30844-6
   PubMed Web of Science ®Google Scholar
• Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:e31. doi: 10.1017/S1462399409001252
   PubMed Web of Science ®Google Scholar
• Patterson S, Fairlamb AH. Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis. Curr Med Chem. 2019;26(23):4454–4475. doi: 10.2174/0929867325666180426164352
   PubMed Web of Science ®Google Scholar
• Gatto M, Oliveira LRC, De Nuzzi Dias F, et al. Benznidazole affects expression of Th1, Th17 and treg cytokines during acute experimental trypanosoma cruzi infection. J Venom Anim Toxins Incl Trop Dis. 2017;23(1):47. doi: 10.1186/s40409-017-0137-4
   PubMedGoogle Scholar
• Maya JD, Cassels BK, Iturriaga-Vásquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol. 2007;146(4):601–620. doi: 10.1016/j.cbpa.2006.03.004
   PubMed Web of Science ®Google Scholar
• Rajão MA, Furtado C, Alves CL, et al. Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in trypanosoma cruzi. Environ Mol Mutagen. 2014;55(4):309–321. doi: 10.1002/em.21839
   PubMed Web of Science ®Google Scholar
• Dias JCP, Novaes Ramos A, Dias Gontijo E, et al. II Consenso Brasileiro em Doença de Chagas, 2015. Epidemiol serv saúde. 2016;25(21):1–10. doi: 10.5123/S1679-49742016002100002
   Google Scholar
• PAHO. Guía para el diagnóstico y el tratamiento de la enfermedad de Chagas. 2018; Available from: https://iris.paho.org/handle/10665.2/49653
   Google Scholar
• González NL, Moscatelli G, Moroni S, et al. Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study. Angheben A, editor. PLOS Negl Trop Dis. 2022;16(12):e0010968. doi: 10.1371/journal.pntd.0010968
   PubMed Web of Science ®Google Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010;115(1–2):55–68. doi: 10.1016/j.actatropica.2009.10.023
   PubMed Web of Science ®Google Scholar
• Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of médecins sans frontières. PLOS Negl Trop Dis. 2009;3(7):e488. doi: 10.1371/journal.pntd.0000488
   PubMed Web of Science ®Google Scholar
• Altcheh J, Castro L, Dib JC, et al. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). Gürtler RE, editor. PlOS Negl Trop Dis. 2021;15(1):e0008912. doi: 10.1371/journal.pntd.0008912
   PubMed Web of Science ®Google Scholar
• Molina-Morant D, Fernández ML, Bosch-Nicolau P, et al. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized phase II non-inferiority clinical trial. Trials. 2020;21(1):328. doi: 10.1186/s13063-020-4226-2
   PubMed Web of Science ®Google Scholar
• Cafferata ML, Toscani MA, Althabe F, et al. Short-course benznidazole treatment to reduce trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol. Reprod Health. 2020;17(1):128. doi: 10.1186/s12978-020-00972-1
   PubMed Web of Science ®Google Scholar
• Alonso-Vega C, Urbina JA, Sanz S, et al. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the plurinational state of Bolivia. BMJ Open. 2021;11(12):e052897. doi: 10.1136/bmjopen-2021-052897
   PubMed Web of Science ®Google Scholar
• Bosch-Nicolau P, Fernández ML, Sulleiro E, et al. Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial. Lancet Infect Dis. 2024;24(4):S386–394. doi: 10.1016/S1473-3099(23)00629-1
   PubMed Web of Science ®Google Scholar
• Molina-Morant D, Fernández ML, Bosch-Nicolau P, et al. Correction: efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized phase II non-inferiority clinical trial. Trials. 2023;24(1):726. doi: 10.1186/s13063-023-07659-5
   PubMed Web of Science ®Google Scholar
• Torrico F, Gascón J, Ortiz L, et al. A phase 2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease. Clin Infect Dis. 2023;76(3):e1186–e1194. doi: 10.1093/cid/ciac579
   PubMed Web of Science ®Google Scholar
• Pinazo M-J, Forsyth C, Losada I, et al. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2024;24(4):S395–403. doi: 10.1016/S1473-3099(23)00651-5
   PubMedGoogle Scholar
• Bahia MT, Diniz LDF, Mosqueira VCF. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opinion On Investigational Drugs. 2014;23(9):1225–1237.
   PubMed Web of Science ®Google Scholar
• Holanda MT, Mediano MFF, Hasslocher-Moreno AM, et al. Effects of selenium treatment on cardiac function in chagas heart disease: results from the STCC randomized trial. EClinicalMedicine. 2021;40:101105. doi: 10.1016/j.eclinm.2021.101105
   PubMedGoogle Scholar
• Araujo-Lima CF, Peres RB, Silva PB, et al. Repurposing strategy of atorvastatin against Trypanosoma cruzi: In Vitro monotherapy and combined therapy with benznidazole exhibit synergistic trypanocidal activity. Antimicrob Agents Chemother. 2018;62(9):62. doi: 10.1128/AAC.00979-18
   Web of Science ®Google Scholar
• Mazzeti AL, Oliveira LT, Gonçalves KR, et al. Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment. Eur J Pharm Sci. 2020;145:105234.
   PubMed Web of Science ®Google Scholar
• Milagre MM, Branquinho RT, Gonçalves MF, et al. Activity of the sesquiterpene lactone goyazensolide against Trypanosoma cruzi in vitro and in vivo. Parasitology. 2020;147(1):108–119. doi: 10.1017/S0031182019001276
   PubMed Web of Science ®Google Scholar
• Torchelsen FKVDS, Silva TM, Milagre MM, et al. Evaluation of the anti-trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole. Parasitol Res. 2021;120:1511–1517. doi: 10.1007/s00436-020-06944-5
   PubMed Web of Science ®Google Scholar
• Cardoso-Santos C, Ferreira De Almeida Fiuza L, França Da Silva C, et al. 7-aryl-7-deazapurine 3′-deoxyribonucleoside derivative as a novel lead for Chagas’ disease therapy: in vitro and in vivo pharmacology. JAC-Antimicrob Resist. 2021;3(4):dlab168. doi: 10.1093/jacamr/dlab168
   PubMedGoogle Scholar
• de Araújo JS, França da Silva C, Batista DDG, et al. Efficacy of novel pyrazolone phosphodiesterase inhibitors in experimental mouse models of Trypanosoma cruzi. Antimicrob Agents Chemother. 2020;64(9):64. doi: 10.1128/AAC.00414-20
   Web of Science ®Google Scholar
• Espinosa R, Robledo S, Guzmán C, et al. Synthesis and evaluation of the in vitro and in vivo antitrypanosomal activity of 2-styrylquinolines. Heliyon. 2021;7(5):e07024. doi: 10.1016/j.heliyon.2021.e07024
   PubMed Web of Science ®Google Scholar
• Lin C, Hulpia F, da Silva CF, et al. Discovery of Pyrrolo[2,3- b]pyridine (1,7-dideazapurine) nucleoside analogues as anti- trypanosoma cruzi agents. J Med Chem. 2019;62(19):8847–8865. doi: 10.1021/acs.jmedchem.9b01275
   PubMed Web of Science ®Google Scholar
• Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81(5):755–759. doi: 10.1016/0035-9203(87)90020-4
   PubMed Web of Science ®Google Scholar
• Vela A, Coral-Almeida M, Sereno D, et al. In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: a systematic review and meta-analysis. Gürtler RE, editor. PLOS Negl Trop Dis. 2021;15(3):e0009269. doi: 10.1371/journal.pntd.0009269
   PubMed Web of Science ®Google Scholar
• Fesser A, Beilstein S, Kaiser M, et al. Trypanosoma cruzi STIB980: a TcI strain for drug discovery and reverse genetics. Pathogens. 2023;12(10):1217. doi: 10.3390/pathogens12101217
   PubMed Web of Science ®Google Scholar
• Teston APM, Fernandes NDS, Abegg CP, et al. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the western Brazilian Amazon. Exp Parasitol. 2021;228:108136. doi: 10.1016/j.exppara.2021.108136
   PubMed Web of Science ®Google Scholar
• Martín-Escolano R, Rosales MJ, Marín C. Biological characteristics of the trypanosoma cruzi arequipa strain make it a good model for Chagas disease drug discovery. Acta Trop. 2022;236:106679. doi: 10.1016/j.actatropica.2022.106679
   PubMed Web of Science ®Google Scholar
• Grosso NL, Bua J, Perrone AE, et al. Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs. Exp Parasitol. 2010;126(2):239–244. doi: 10.1016/j.exppara.2010.05.010
   PubMed Web of Science ®Google Scholar
• Chatelain E, Scandale I. Animal models of Chagas disease and their translational value to drug development. Expert Opin Drug Discov. 2020;15(12):1381–1402.
   PubMed Web of Science ®Google Scholar
• Mateus J, Guerrero P, Lasso P, et al. An animal model of acute and chronic Chagas disease with the reticulotropic Y strain of trypanosoma cruzi that depicts the multifunctionality and dysfunctionality of T cells. Front Immunol. 2019;10:918. doi: 10.3389/fimmu.2019.00918
   PubMed Web of Science ®Google Scholar
• Bahia MT, Andrade ID, Martins TAF, et al. Fexinidazole: a potential new drug candidate for chagas disease. Pollastri MP, editor. PLOS Negl Trop Dis. 2012;6(11):e1870. doi: 10.1371/journal.pntd.0001870
   PubMed Web of Science ®Google Scholar
• Bahia MT, Nascimento AFS, Mazzeti AL, et al. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for chagas disease. Antimicrob Agents Chemother. 2014;58(8):4362–4370. doi: 10.1128/AAC.02754-13
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Gonçalves KR, Mota SLA, et al. Combination therapy using nitro compounds improves the efficacy of experimental chagas disease treatment. Parasitology. 2021;148(11):1320–1327. doi: 10.1017/S0031182021001001
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Diniz LDF, Gonçalves KR, et al. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following trypanosoma cruzi infection: a pre-clinical study. Biochem Pharmacol. 2018;148:213–221.
   PubMed Web of Science ®Google Scholar
• Moraes CB, Giardini MA, Kim H, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for chagas disease drug discovery and development. Sci Rep. 2015;4(1):4703. doi: 10.1038/srep04703
   Web of Science ®Google Scholar
• Buckner FS.Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Adv Parasitol [Internet]. Elsevier. 2011 [cited 2024 Apr 3]. 89–119. Elsevier: https://linkinghub.elsevier.com/retrieve/pii/B9780123858634000058
   Google Scholar
• Chatelain E. Chagas disease research and development: is there light at the end of the tunnel? Comput Struct Biotechnol J. 2017;15:98–103. doi: 10.1016/j.csbj.2016.12.002
   PubMed Web of Science ®Google Scholar
• Romanha AJ, Castro SD, Soeiro MDN, et al. In vitro and in vivo experimental models for drug screening and development for chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–238. doi: 10.1590/S0074-02762010000200022
   PubMed Web of Science ®Google Scholar
• Moon S, Siqueira-Neto JL, Moraes CB, et al. An Image-Based Algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi. Rodrigues MM, editor. PLOS ONE. 2014;9(2):e87188. doi: 10.1371/journal.pone.0087188
   PubMed Web of Science ®Google Scholar
• De Rycker M, Thomas J, Riley J, et al. Identification of trypanocidal activity for known clinical compounds using a new trypanosoma cruzi hit-discovery screening cascade. Burleigh BA, editor. PlOS Negl Trop Dis. 2016;10(4):e0004584. doi: 10.1371/journal.pntd.0004584
   PubMed Web of Science ®Google Scholar
• Branquinho RT, de Mello CGC, Oliveira MT, et al. Lychnopholide in Poly(D,L-lactide)-block-polyethylene glycol nanocapsules cures infection with a drug-resistant Trypanosoma cruzi strain at acute and chronic phases. Antimicrob Agents Chemother. 2020;64:e01937–19,/aac/64/4/AAC.01937–19.atom.
   Web of Science ®Google Scholar
• de Mello CGC, Branquinho RT, Oliveira MT, et al. Efficacy of lychnopholide polymeric nanocapsules after oral and intravenous administration in murine experimental chagas disease. Antimicrob Agents Chemother. 2016;60:5215–5222. doi: 10.1128/AAC.00178-16
   PubMed Web of Science ®Google Scholar
• Branquinho RT, Mosqueira VCF, de Oliveira-Silva JCV, et al. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental chagas disease. Antimicrob Agents Chemother. 2014;58(4):2067–2075. doi: 10.1128/AAC.00617-13
   PubMed Web of Science ®Google Scholar
• Rial MS, Reigada C, Prado N, et al. Effectiveness of the repurposed drug isotretinoin in an experimental murine model of chagas disease. Acta Trop. 2023;242:106920. doi: 10.1016/j.actatropica.2023.106920
   PubMed Web of Science ®Google Scholar
• Olivera GC, Postan M, González MN. Effects of artesunate against Trypanosoma cruzi. Exp Parasitol. 2015;156:26–31. doi: 10.1016/j.exppara.2015.05.014
   PubMed Web of Science ®Google Scholar
• Pandey RP, Nascimento MS, Franco CH, et al. Drug repurposing in chagas disease: chloroquine potentiates benznidazole activity against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2022;66(11):e00284–22. doi: 10.1128/aac.00284-22
   PubMed Web of Science ®Google Scholar
• Martinez-Peinado N, Martori C, Cortes-Serra N, et al. Anti-trypanosoma cruzi activity of metabolism modifier compounds. Int J Mol Sci. 2021;22(2):688. doi: 10.3390/ijms22020688
   PubMed Web of Science ®Google Scholar
• Gulin JEN, Eagleson MA, López-Muñoz RA, et al. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models. Acta Trop. 2020;211:105606. doi: 10.1016/j.actatropica.2020.105606
   PubMed Web of Science ®Google Scholar
• Machado YA, Bahia MT, Caldas IS, et al. Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection. Antimicrob Agents Chemother. 2020;64(8):e02497–19,/aac/64/8/AAC.02497–19.atom. doi: 10.1128/AAC.02497-19
   Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Nitrotriazole-based compounds as antichagasic agents in a long-treatment in vivo assay. Antimicrob Agents Chemother. 2017;61(5):e02717–16, e02717–16. doi: 10.1128/AAC.02717-16
   Web of Science ®Google Scholar
• Álvarez G, Varela J, Cruces E, et al. Identification of a new amide-containing thiazole as a drug candidate for treatment of chagas’ disease. Antimicrob Agents Chemother. 2015;59(3):1398–1404. doi: 10.1128/AAC.03814-14
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Lepesheva GI, et al. Novel 3-nitrotriazole-based amides and Carbinols as bifunctional antichagasic agents. J Med Chem. 2015;58(3):1307–1319. doi: 10.1021/jm5015742
   PubMed Web of Science ®Google Scholar
• Moraes CB, White KL, Braillard S, et al. Enantiomers of nifurtimox do not exhibit stereoselective anti-trypanosoma cruzi activity, toxicity, or pharmacokinetic properties. Antimicrob Agents Chemother. 2015;59(6):3645–3647. doi: 10.1128/AAC.05139-14
   PubMed Web of Science ®Google Scholar
• Keenan M, Chaplin JH, Alexander PW, et al. Two analogues of fenarimol show curative activity in an experimental model of chagas disease. J Med Chem. 2013;56(24):10158–10170. doi: 10.1021/jm401610c
   PubMed Web of Science ®Google Scholar
• Soeiro MDN, de Souza EM, da Silva CF, et al. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2013;57(9):4151–4163. doi: 10.1128/AAC.00070-13
   PubMed Web of Science ®Google Scholar
• Villalta F, Dobish MC, Nde PN, et al. VNI cures acute and chronic experimental chagas disease. J Infect Dis. 2013;208(3):504–511. doi: 10.1093/infdis/jit042
   PubMed Web of Science ®Google Scholar
• Guedes-da-Silva FH, Batista DGJ, Da Silva CF, et al. Antitrypanosomal activity of sterol 14α-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of chagas disease induced by the trypanosoma cruzi Y strain. Antimicrob Agents Chemother. 2017;61(4):e02098–16, e02098–16. doi: 10.1128/AAC.02098-16
   Web of Science ®Google Scholar
• Guedes-da-Silva FH, Batista DGJ, da Silva CF, et al. Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of trypanosoma cruzi infection. Antimicrob Agents Chemother. 2015;59(12):7564–7570. doi: 10.1128/AAC.01294-15
   PubMed Web of Science ®Google Scholar
• Spósito PÁ, Mazzeti AL, de Castro KCMP, et al. Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease. Exp Parasitol. 2021;228:108142. doi: 10.1016/j.exppara.2021.108142
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Gonçalves KR, Boasquívis PF, et al. Poly-ε-caprolactone implants for benznidazole prolonged release: an alternative to chagas disease oral treatment. Pharmaceutics. 2023;15(4):1126. doi: 10.3390/pharmaceutics15041126.
   PubMed Web of Science ®Google Scholar
• Zingales B, Miles MA, Moraes CB, et al. Drug discovery for chagas disease should consider trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz. 2014;109(6):828–833. doi: 10.1590/0074-0276140156
   PubMed Web of Science ®Google Scholar
• Milagre MM, Torchelsen FKVDS, Pedrosa TCF, et al. Lychnopholide loaded in surface modified polylactide nanocapsules (LYC-PLA-PEG-NC) cure mice infected by Trypanosoma cruzi strain a prototype of resistance to benznidazole and nifurtimox: first insights of its mechanism of action. Experimental Parasitology. 2023;255:108647. doi: 10.1016/j.exppara.2023.108647
   PubMed Web of Science ®Google Scholar
• Guedes-da-Silva FH, Batista DGJ, Meuser MB, et al. In vitro and in vivo trypanosomicidal action of novel arylimidamides against Trypanosoma cruzi. Antimicrob Agents Chemother. 2016;60(4):2425–2434. doi: 10.1128/AAC.01667-15
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Discovery of potent nitrotriazole-based antitrypanosomal agents: in vitro and in vivo evaluation. Bioorg Med Chem. 2015;23(19):6467–6476. doi: 10.1016/j.bmc.2015.08.014
   PubMed Web of Science ®Google Scholar
• Russell WMS, Burch RL. The principles of humane experimental technique. Med J Aust. 1960;1:500–500.
   Google Scholar
• De Lana M, Martins-Filho OA. Revisiting the posttherapeutic cure criterion in chagas disease: time for new methods, more questions, doubts, and polemics or time to change old concepts? Biomed Res Int. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Machado-de-Assis GF, Silva AR, Do Bem VAL, et al. Posttherapeutic cure criteria in chagas’ disease: conventional serology followed by supplementary serological, parasitological, and molecular tests. Clin Vaccine Immunol. 2012;19(8):1283–1291. doi: 10.1128/CVI.00274-12
   PubMed Web of Science ®Google Scholar
• Katsuno K, Burrows JN, Duncan K, et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat Rev Drug Discov. 2015;14(11):751–758. doi: 10.1038/nrd4683
   PubMed Web of Science ®Google Scholar
• Cerecetto H, González M. Synthetic medicinal chemistry in chagas’ disease: compounds at the final stage of “hit-to-lead” phase. Pharmaceuticals. 2010;3:810–838. doi: 10.3390/ph3040810
   Google Scholar
• Keenan M, Alexander PW, Diao H, et al. Design, structure–activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi. Bioorg Med Chem. 2013;21(7):1756–1763. doi: 10.1016/j.bmc.2013.01.050
   PubMed Web of Science ®Google Scholar
• Keenan M, Abbott MJ, Alexander PW, et al. Analogues of fenarimol are potent inhibitors of trypanosoma cruzi and are efficacious in a murine model of chagas disease. J Med Chem. 2012;55(9):4189–4204. doi: 10.1021/jm2015809
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity. Eur J Med Chem. 2016;123:895–904. doi: 10.1016/j.ejmech.2016.08.002
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. 3-nitrotriazole-based piperazides as potent antitrypanosomal agents. Eur J Med Chem. 2015;103:325–334. doi: 10.1016/j.ejmech.2015.08.042
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. Eur J Med Chem. 2014;87:79–88. doi: 10.1016/j.ejmech.2014.09.045
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-chagasic drugs: in vivo studies. Future Med Chem. 2013;5(15):1763–1776. doi: 10.4155/fmc.13.108
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. Bioorg Med Chem. 2013;21(21):6600–6607. doi: 10.1016/j.bmc.2013.08.022
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Bloomer WD, Rosenzweig HS, et al. Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents. J Med Chem. 2012;55(11):5554–5565. doi: 10.1021/jm300508n
   PubMed Web of Science ®Google Scholar
• Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents. J Med Chem. 2011;54(23):8214–8223. doi: 10.1021/jm201215n
   PubMed Web of Science ®Google Scholar
• Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology. 2013;140(8):929–951. doi: 10.1017/S0031182013000292
   PubMed Web of Science ®Google Scholar
• Batista DDG, Batista MM, de Oliveira GM, et al. Arylimidamide DB766, a potential chemotherapeutic candidate for chagas’ disease treatment. Antimicrob Agents Chemother. 2010;54(7):2940–2952. doi: 10.1128/AAC.01617-09
   PubMed Web of Science ®Google Scholar
• da Silva CF, Batista DDG, de Araújo JS, et al. Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of trypanosoma cruzi infection. Drug Des Devel Ther. 2017;11:1095–1105. doi: 10.2147/DDDT.S120618
   PubMed Web of Science ®Google Scholar
• da Silva CF, Batista DDG, Oliveira GM, et al. In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form–DB1965–against Trypanosoma cruzi infection. PLOS One. 2012;7(1):e30356. doi: 10.1371/journal.pone.0030356
   PubMed Web of Science ®Google Scholar
• Liu Z, Wenzler T, Brun R, et al. Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups. Eur J Med Chem. 2014;83:167–173. doi: 10.1016/j.ejmech.2014.06.022
   PubMed Web of Science ®Google Scholar
• Santos CC, Lionel JR, Peres RB, et al. In vitro, in Silico, and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi. Silico, and in vivo analyses of novel aromatic amidines against Trypanosoma cruzi. Antimicrob Agents Chemother. 2018;62(2):62. doi: 10.1128/AAC.02205-17
   Web of Science ®Google Scholar
• Timm BL, da Silva PB, Batista MM, et al. In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi. Antimicrob Agents Chemother. 2014;58(7):3720–3726. doi: 10.1128/AAC.02353-14
   PubMed Web of Science ®Google Scholar
• Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother. 2005;49(12):5160–5161. doi: 10.1128/AAC.49.12.5160-5161.2005
   PubMed Web of Science ®Google Scholar
• Brak K, Kerr ID, Barrett KT, et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for chagas disease chemotherapy. J Med Chem. 2010;53(4):1763–1773. doi: 10.1021/jm901633v
   PubMed Web of Science ®Google Scholar
• Cardoso MDO, de Siqueira LRP, da Silva EB, et al. 2-pyridyl thiazoles as novel anti-trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation. Eur J Med Chem. 2014;86:48–59. doi: 10.1016/j.ejmech.2014.08.012
   PubMed Web of Science ®Google Scholar
• da Silva EB, Oliveira E, DA S, et al. Desing and synthesis of potent anti-trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death. Eur J Med Chem. 2017;130:39–50. doi: 10.1016/j.ejmech.2017.02.026
   PubMed Web of Science ®Google Scholar
• de Oliveira Filho GB, Cardoso MDOO, Espíndola JWP, et al. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi. Eur J Med Chem. 2017;141:346–361. doi: 10.1016/j.ejmech.2017.09.047
   PubMed Web of Science ®Google Scholar
• de Oliveira Filho GB, de Oliveira Cardoso MV, Espíndola JWP, et al. Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi. Bioorg Med Chem. 2015;23(23):7478–7486. doi: 10.1016/j.bmc.2015.10.048
   PubMed Web of Science ®Google Scholar
• Ndao M, Beaulieu C, Black WC, et al. Reversible cysteine protease inhibitors show promise for a chagas disease cure. Antimicrob Agents Chemother. 2014;58(2):1167–1178. doi: 10.1128/AAC.01855-13
   PubMed Web of Science ®Google Scholar
• Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, et al. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: overview and current state of the art. Biomed Pharmacother. 2018;102:608–617. doi: 10.1016/j.biopha.2018.03.102
   PubMed Web of Science ®Google Scholar
• Saccoliti F, Di Santo R, Costi R. Recent advancement in the search of innovative antiprotozoal agents targeting trypanothione metabolism. ChemMedchem. 2020;15(24):2420–2435. doi: 10.1002/cmdc.202000325
   PubMed Web of Science ®Google Scholar
• Moreira TDB, Barbosa AFS, Veiga-Santos P, et al. Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi. Int J Antimicrob Agents. 2013;41:183–187. doi: 10.1016/j.ijantimicag.2012.09.018
   PubMed Web of Science ®Google Scholar
• Olmo F, Cussó O, Marín C, et al. In vitro and in vivo identification of tetradentated polyamine complexes as highly efficient metallodrugs against Trypanosoma cruzi. Exp Parasitol. 2016;164:20–30. doi: 10.1016/j.exppara.2016.02.004
   PubMed Web of Science ®Google Scholar
• Hulpia F, Van Hecke K, França da Silva C, et al. Discovery of novel 7-aryl 7-deazapurine 3′-deoxy-ribofuranosyl nucleosides with potent activity against Trypanosoma cruzi. J Med Chem. 2018;61(20):9287–9300. doi: 10.1021/acs.jmedchem.8b00999
   PubMed Web of Science ®Google Scholar
• Bastos JK, Albuquerque S, Silva MLA. Evaluation of the trypanocidal activity of lignans isolated from the leaves of zanthoxylum naranjillo. Planta Med. 1999;65(6):541–544. doi: 10.1055/s-1999-14012
   PubMed Web of Science ®Google Scholar
• Ferreira ME, Nakayama H, de Arias AR, et al. Effects of canthin-6-one alkaloids from Zanthoxylum chiloperone on trypanosoma cruzi-infected mice. J Ethnopharmacol. 2007;109(2):258–263. doi: 10.1016/j.jep.2006.07.028
   PubMed Web of Science ®Google Scholar
• Jimenez-Coello M, Acosta-Viana KY, Guzman-Marin E, et al. Anti-trypanosomal activity of (8-hydroxymethylen)-trieicosanyl acetate against infective forms of trypanosoma cruzi. Pharm Biol. 2010;48(6):666–671. doi: 10.3109/13880200903241853
   PubMed Web of Science ®Google Scholar
• Ferreira ME, Cebrián-Torrejón G, Corrales AS, et al. Zanthoxylum chiloperone leaves extract: first sustainable chagas disease treatment. J Ethnopharmacol. 2011;133(3):986–993. doi: 10.1016/j.jep.2010.11.032
   PubMed Web of Science ®Google Scholar
• Marín C, Ramírez- Macímacías I, López-Céspedes A, et al. In vitro and in vivo trypanocidal activity of flavonoids from delphinium staphisagria against chagas disease. J Nat Prod. 2011;74(4):744–750. doi: 10.1021/np1008043
   PubMed Web of Science ®Google Scholar
• Jiménez-Coello M, Acosta-Viana K, Pérez M, et al. In vivo activity of (8-hydroxymethylen)-trieicosanyl acetate against Trypanosoma cruzi during acute phase of the infection. Afr J Tradit Complement Altern Med [Internet]. 2011 [cited 2020 Dec 1]; 8(5S). Available from: http://www.ajol.info/index.php/ajtcam/article/view/67996
   Google Scholar
• Meira CS, Guimarães ET, Bastos TM, et al. Physalins B and F, seco-steroids isolated from physalis angulata L. strongly inhibit proliferation, ultrastructure and infectivity of Trypanosoma cruzi. Parasitology. 2013;140(14):1811–1821. doi: 10.1017/S0031182013001297
   PubMed Web of Science ®Google Scholar
• Jimenez-Coello M, Acosta-Viana KY, Ortega-Pacheco A, et al. In vivo antiprotozoal activity of the chloroform extract from carica papaya seeds against amastigote stage of trypanosoma cruzi during indeterminate and chronic phase of infection. Evid-Based Complement Altern Med ECAM. 2014;2014:458263. doi: 10.1155/2014/458263
   PubMed Web of Science ®Google Scholar
• Varela J, Serna E, Torres S, et al. In vivo anti-trypanosoma cruzi activity of hydro-ethanolic extract and isolated active principles from Aristeguietia glutinosa and mechanism of action studies. Mol. 2014;19(6):8488–8502. doi: 10.3390/molecules19068488
   PubMed Web of Science ®Google Scholar
• da Rocha CQ, Queiroz EF, Meira CS, et al. Dimeric flavonoids from arrabidaea brachypoda and assessment of their anti- trypanosoma cruzi activity. J Nat Prod. 2014;77(6):1345–1350. doi: 10.1021/np401060j
   PubMed Web of Science ®Google Scholar
• Meira CS, Guimarães ET, Dos Santos JAF, et al. In vitro and in vivo antiparasitic activity of physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi. Phytomedicine Int J Phytother Phytopharm. 2015;22(11):969–974. doi: 10.1016/j.phymed.2015.07.004
   PubMed Web of Science ®Google Scholar
• Lozano E, Strauss M, Spina R, et al. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from salvia gilliesii. Parasitol Int. 2016;65(1):23–26. doi: 10.1016/j.parint.2015.08.011
   PubMed Web of Science ®Google Scholar
• García-Huertas P, Olmo F, Sánchez-Moreno M, et al. Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from piper jericoense. Exp Parasitol. 2018;189:34–42. doi: 10.1016/j.exppara.2018.04.009
   PubMed Web of Science ®Google Scholar
• Mishina YV, Krishna S, Haynes RK, et al. Artemisinins Inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense In Vitro Growth. Antimicrob Agents Chemother. 2007;51(5):1852–1854. doi: 10.1128/AAC.01544-06
   PubMed Web of Science ®Google Scholar
• Chadwick M, Trewin H, Gawthrop F, et al. Sesquiterpenoids lactones: benefits to plants and people. Int J Mol Sci. 2013;14(6):12780–12805. doi: 10.3390/ijms140612780
   PubMed Web of Science ®Google Scholar
• Branquinho RT, Roy J, Farah C, et al. Biodegradable polymeric nanocapsules prevent cardiotoxicity of Anti-Trypanosomal Lychnopholide. Sci Rep. 2017;7(1):44998. doi: 10.1038/srep44998
   PubMedGoogle Scholar
• Laurella LC, Cerny N, Bivona AE, et al. Assessment of sesquiterpene lactones isolated from mikania plants species for their potential efficacy against Trypanosoma cruzi and Leishmania sp. Schallig HDFH, editor. PloS Negl Trop Dis. 2017;11(9):e0005929. doi: 10.1371/journal.pntd.0005929
   PubMed Web of Science ®Google Scholar
• Alberti AS, Cerny N, Bivona A, et al. Antitrypanosomal and antileishmanial activities. In: Sülsen V, Martino V, editors. Sesquiterpene lact, [internet]. Cham: Springer International Publishing; 2018 [cited 2020 Dec 3]; p. 175–196. Available from: https://doi.org/10.1007/978-3-319-78274-4_8
   Google Scholar
• Gonçalves-Santos E, Vilas-Boas DF, Diniz LF, et al. Sesquiterpene lactone potentiates the immunomodulatory, antiparasitic and cardioprotective effects on anti-trypanosoma cruzi specific chemotherapy. Int Immunopharmacol. 2019;77:105961. doi: 10.1016/j.intimp.2019.105961
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg. 1986;35(2):280–284. doi: 10.4269/ajtmh.1986.35.280
   PubMed Web of Science ®Google Scholar
• McCabe RE, Remington JS, Araujo FG. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg. 1987;81(4):613–615. doi: 10.1016/0035-9203(87)90430-5
   PubMed Web of Science ®Google Scholar
• Goad LJ, Berens RL, Marr JJ, et al. The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitro. Mol Biochem Parasitol. 1989;32(2–3):179–189. doi: 10.1016/0166-6851(89)90069-8
   PubMed Web of Science ®Google Scholar
• Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (schizotrypanum) cruzi. Antimicrob Agents Chemother. 1990;34(11):2097–2105. doi: 10.1128/AAC.34.11.2097
   PubMed Web of Science ®Google Scholar
• Araujo MSS, Martins-Filho OA, Pereira MES, et al. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental chagas’ disease. J Antimicrob Chemother. 2000;45(6):819–824. doi: 10.1093/jac/45.6.819
   PubMed Web of Science ®Google Scholar
• Molina J. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite trypanosoma cruzi. J Antimicrob Chemother. 2000;46(1):137–140. doi: 10.1093/jac/46.1.137
   PubMed Web of Science ®Google Scholar
• Toledo MDO, Bahia MT, Carneiro CM, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother. 2003;47(1):223–230. doi: 10.1128/AAC.47.1.223-230.2003
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on trypanosoma cruzi, the causative agent of chagas disease. Int J Antimicrob Agents. 2003;21(1):27–38. doi: 10.1016/S0924-8579(02)00273-X
   PubMed Web of Science ®Google Scholar
• Guedes PDM, Urbina JA, de Lana M, et al. Activity of the new triazole derivative albaconazole against Trypanosoma (schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother. 2004;48(11):4286–4292. doi: 10.1128/AAC.48.11.4286-4292.2004
   PubMed Web of Science ®Google Scholar
• Benaim G, Sanders JM, Garcia-Marchán Y, et al. Amiodarone has intrinsic anti- Trypanosoma c ruzi activity and acts synergistically with posaconazole †. J Med Chem. 2006;49(3):892–899. doi: 10.1021/jm050691f
   PubMed Web of Science ®Google Scholar
• Diniz LDF, Caldas IS, Guedes PDM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother. 2010;54(7):2979–2986. doi: 10.1128/AAC.01742-09
   PubMed Web of Science ®Google Scholar
• Diniz LDF, Urbina JA, de Andrade IM, et al. Benznidazole and posaconazole in experimental chagas disease: positive interaction in concomitant and sequential treatments. Rodrigues MM, editor. PloS Negl Trop Dis. 2013;7(8):e2367. doi: 10.1371/journal.pntd.0002367
   PubMed Web of Science ®Google Scholar
• Assíria Fontes Martins T, de Figueiredo Diniz L, Mazzeti AL, et al. Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease. Costa FTM, editor. PLoS One. 2015;10(6):e0128707. doi: 10.1371/journal.pone.0128707
   PubMed Web of Science ®Google Scholar
• Diniz LDF, Mazzeti AL, Caldas IS, et al. Outcome of E1224-benznidazole combination treatment for infection with a multidrug-resistant trypanosoma cruzi strain in mice. Antimicrob Agents Chemother. 2018;62(6):e00401–18. doi: 10.1128/AAC.00401-18
   PubMed Web of Science ®Google Scholar
• Cencig S, Coltel N, Truyens C, et al. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents. 2012;40(6):527–532. doi: 10.1016/j.ijantimicag.2012.08.002
   PubMed Web of Science ®Google Scholar
• Buckner FS, Bahia MT, Suryadevara PK, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-chagas disease lead compounds derived from Tipifarnib. Antimicrob Agents Chemother. 2012;56(9):4914–4921. doi: 10.1128/AAC.06244-11
   PubMed Web of Science ®Google Scholar
• Hucke O, Gelb MH, Verlinde CLMJ, et al. The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against chagas disease. J Med Chem. 2005;48(17):5415–5418. doi: 10.1021/jm050441z
   PubMed Web of Science ®Google Scholar
• Kraus JM, Tatipaka HB, McGuffin SA, et al. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-chagas disease drug discovery. J Med Chem. 2010;53(10):3887–3898. doi: 10.1021/jm9013136
   PubMed Web of Science ®Google Scholar
• Simões-Silva MR, De Araújo JS, Peres RB, et al. Repurposing strategies for chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi. Parasitology. 2019;146(8):1006–1012. doi: 10.1017/S0031182019000234
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Craft JM, Crowe BD, et al. New, combined, and reduced dosing treatment protocols cure trypanosoma cruzi infection in mice. J Infect Dis. 2014;209(1):150–162. doi: 10.1093/infdis/jit420
   PubMed Web of Science ®Google Scholar
• Echeverría LE, González CI, Hernandez JCM, et al. Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: an experimental murine model of acute chagas. Rev Soc Bras Med Trop. 2020;53:e20190477. doi: 10.1590/0037-8682-0477-2019
   PubMed Web of Science ®Google Scholar
• Guedes-da-Silva FH, Batista DDG, Da Silva CF, et al. Successful aspects of the coadministration of sterol 14α-demethylase inhibitor VFV and benznidazole in experimental mouse models of chagas disease caused by the drug-resistant strain of Trypanosoma cruzi. ACS Infect Dis. 2019;5(3):365–371. doi: 10.1021/acsinfecdis.8b00253
   PubMed Web of Science ®Google Scholar
• da Silva RM, Oliveira LT, Silva Barcellos NM, et al. Preclinical monitoring of drug association in experimental chemotherapy of chagas’ disease by a new HPLC-UV method. Antimicrob Agents Chemother. 2012;56(6):3344–3348. doi: 10.1128/AAC.05785-11
   PubMed Web of Science ®Google Scholar
• Cunha ELA, Torchelsen FDS, Cunha LM, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs. Exp Parasitol. 2019;204:107711. doi: 10.1016/j.exppara.2019.05.005
   PubMed Web of Science ®Google Scholar
• Cunha ELA, Torchelsen FDS, Cunha LM, et al. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs. MethodsX. 2019;6:2544–2552. doi: 10.1016/j.mex.2019.10.007
   PubMed Web of Science ®Google Scholar
• Carrillo I, Rabelo RAN, Barbosa C, et al. Aspirin-triggered resolvin D1 reduces parasitic cardiac load by decreasing inflammation in a murine model of early chronic chagas disease. Santiago HDC, editor. PloS Negl Trop Dis. 2021;15(11):e0009978. doi: 10.1371/journal.pntd.0009978
   PubMed Web of Science ®Google Scholar
• Horta AL, Figueiredo VP, Leite ALJ, et al. The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the trypanosoma cruzi. Mem Inst Oswaldo Cruz [Internet]. 2018 [cited 2023 Jul 27]; 113(11). Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762018001100301&lng=en&tlng=en
   Google Scholar
• Leite ALJ, Paula Costa GD, Lopes LR, et al. The immunomodulatory effects of the enalapril in combination with benznidazole during acute and chronic phases of the experimental infection with Trypanosoma cruzi. Acta Trop. 2017;174:136–145. doi: 10.1016/j.actatropica.2017.07.005
   PubMed Web of Science ®Google Scholar
• Penitente AR, Leite ALJ, de Paula Costa G, et al. Enalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi. Am J Trop Med Hyg. 2015;93(5):976–982. doi: 10.4269/ajtmh.15-0237
   PubMed Web of Science ®Google Scholar
• Shrestha D, Penitente AR, Horta AL, et al. Enalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi. Am J Trop Med Hyg. 2015;93(5):976–982. doi: 10.4269/ajtmh.15-0237
   PubMed Web of Science ®Google Scholar
• Grosso NL, Alarcon ML, Bua J, et al. Combined treatment with benznidazole and allopurinol in mice infected with a virulent trypanosoma cruzi isolate from Nicaragua. Parasitology. 2013;140(10):1225–1233. doi: 10.1017/S0031182013000176
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Diniz LDF, Gonçalves KR, et al. Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi. Antimicrob Agents Chemother. 2019;63(6):e02264–18,/aac/63/6/AAC.02264–18.atom. doi: 10.1128/AAC.02264-18
   Web of Science ®Google Scholar
• Perez-Mazliah DE, Alvarez MG, Cooley G, et al. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother. 2013;68(2):424–437. doi: 10.1093/jac/dks390
   PubMed Web of Science ®Google Scholar
• Rial MS, Scalise ML, López Alarcón M, et al. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of trypanosoma cruzi chronic infection. Parasitology. 2019;146(3):305–313. doi: 10.1017/S0031182018001567
   PubMed Web of Science ®Google Scholar
• Veiga-Santos P, Barrias ES, Santos JFC, et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2012;40(1):61–71. doi: 10.1016/j.ijantimicag.2012.03.009
   PubMed Web of Science ®Google Scholar
• Rocha Simões-Silva M, Brandão Peres R, Britto C, et al. Impact of levamisole in co-administration with benznidazole on experimental chagas disease. Parasitology. 2019;146:1055–1062. doi: 10.1017/S0031182019000374
   PubMed Web of Science ®Google Scholar
• Simões-Silva MR, De Araújo JS, Oliveira GM, et al. Drug repurposing strategy against Trypanosoma cruzi infection: in vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy. Biochem Pharmacol. 2017;145:46–53. doi: 10.1016/j.bcp.2017.08.025
   PubMed Web of Science ®Google Scholar
• Fonseca-Berzal C, da Silva CF, Batista DDG, et al. Activity profile of two 5-nitroindazole derivatives over the moderately drug-resistant trypanosoma cruzi Y strain (DTU TcII): in vitro and in vivo studies. Parasitology. 2020;147(11):1216–1228. doi: 10.1017/S0031182020000955
   PubMed Web of Science ®Google Scholar
• Vilas-Boas DF, Oliveira RRG, Gonçalves-Santos E, et al. 4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute trypanosoma cruzi infection. Acta Trop. 2022;228:106314. doi: 10.1016/j.actatropica.2022.106314
   PubMed Web of Science ®Google Scholar
• González S, Wall RJ, Thomas J, et al. Short-course combination treatment for experimental chronic chagas disease. Sci Transl Med. 2023;15(726):eadg8105. doi: 10.1126/scitranslmed.adg8105
   PubMed Web of Science ®Google Scholar
• Mosqueira VCF, Mazzeti AL, Bahia MT. Nanomedicines against chagas disease. Appl Nanobiotechnology Neglected Trop Dis [Internet]. 2021 cited 2021 Feb 27;169–189. Elsevier Available from: https://linkinghub.elsevier.com/retrieve/pii/B978012821100700008X
   Google Scholar
• Esteva MI, Rial MS, Scalise ML, et al. Promising efficacy of benznidazole nanoparticles in acute trypanosoma cruzi murine model: In-vitro and in-vivo studies. Am J Trop Med Hyg. 2016;95(2):388–393. doi: 10.4269/ajtmh.15-0889
   PubMed Web of Science ®Google Scholar
• Rial MS, Arrúa EC, Natale MA, et al. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of trypanosoma cruzi Nicaragua infection in mice. J Antimicrob Chemother. 2020;75(7):1906–1916. doi: 10.1093/jac/dkaa101
   PubMed Web of Science ®Google Scholar
• Molina I, Perin L, Aviles AS, et al. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Acta Trop. 2020;201:105218. doi: 10.1016/j.actatropica.2019.105218
   PubMed Web of Science ®Google Scholar
• Perin L, da S FK, de Carvalho TV, et al. Low-dose of benznidazole promotes therapeutic cure in experimental chronic chagas’ disease with absence of parasitism in blood, heart and colon. Exp Parasitol. 2020;210:107834. doi: 10.1016/j.exppara.2020.107834
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Sanchez-Valdez F, Padilla AM, et al. A modified drug regimen clears active and dormant trypanosomes in mouse models of chagas disease. Sci Transl Med. 2020;12(567). doi: 10.1126/scitranslmed.abb7656
   PubMed Web of Science ®Google Scholar
• Rao SPS, Gould MK, Noeske J, et al. Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections. Science. 2023;380(6652):1349–1356. doi: 10.1126/science.adh0614
   PubMed Web of Science ®Google Scholar
• Campos MCO, Leon LL, Taylor MC, et al. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol Biochem Parasitol. 2014;193(1):17–19. doi: 10.1016/j.molbiopara.2014.01.002
   PubMed Web of Science ®Google Scholar
• Petravicius PO, Costa-Martins AG, Silva MN, et al. Mapping benznidazole resistance in trypanosomatids and exploring evolutionary histories of nitroreductases and ABCG transporter protein sequences. Acta Trop. 2019;200:105161. doi: 10.1016/j.actatropica.2019.105161
   PubMed Web of Science ®Google Scholar
• Zingales B. Trypanosoma cruzi genetic diversity: something new for something known about chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2018;184:38–52. doi: 10.1016/j.actatropica.2017.09.017
   PubMed Web of Science ®Google Scholar
• Moreno M, D’ávila DA, Silva MN, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human chagas disease. Mem Inst Oswaldo Cruz. 2010;105(7):918–924. doi: 10.1590/S0074-02762010000700014
   PubMed Web of Science ®Google Scholar
• Sánchez-Valdéz FJ, Padilla A, Wang W, et al. Spontaneous dormancy protects trypanosoma cruzi during extended drug exposure. Elife. 2018;7. doi: 10.7554/eLife.34039
   PubMed Web of Science ®Google Scholar
• Chatelain E, Ioset J-R. Phenotypic screening approaches for chagas disease drug discovery. Expert Opin Drug Discov. 2018;13(2):141–153. doi: 10.1080/17460441.2018.1417380
   PubMed Web of Science ®Google Scholar
• Kratz JM, Gonçalves KR, Romera LM, et al. The translational challenge in chagas disease drug development. Mem Inst Oswaldo Cruz. 2022;117:e200501. doi: 10.1590/0074-02760200501
   PubMed Web of Science ®Google Scholar